United Therapeutics (UTHR) Earnings Date & Reports

United Therapeutics posted total revenues of $781.5 million for the quarter ended March 31, 2026, a 2% decrease from $794.4 million in Q1 2025 and below consensus estimates of approximately $797 million. Net product sales, comprising 100% of revenues, reflected mixed performance across the portfolio.

Tyvaso, the top seller, generated $457.5 million (down 2% YoY), with Tyvaso DPI up 9% to $330.3 million on higher volumes and pricing, offset by a 22% drop in nebulized Tyvaso to $127.2 million due to lower U.S. shipments. Orenitram hit a record $135.6 million (up 12%), driven by volume growth. Remodulin fell 8% to $126.6 million, Unituxin declined 8% to $53.6 million, and Adcirca dropped sharply to $2.9 million.

Net income was $274.9 million (down 15% YoY), yielding diluted EPS of $5.82 (down 12% from $6.63), missing expectations around $7.00. Higher cost of sales (up 44% to $133.4 million, including Tyvaso DPI inventory reserve) and SG&A (up 8%) pressured margins. No updated full-year guidance was provided, but management committed to sequential quarterly revenue growth. U.S. revenues dominated at 95% ($744.2 million).

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of biotech names like UTHR.

Market Reaction and Investor Sentiment

UTHR shares dipped about 3.8% in pre-market trading post-release, reflecting disappointment over the revenue and EPS misses amid higher costs. However, the stock later rebounded, rising over 2% in subsequent trading, buoyed by positive clinical data from ADVANCE OUTCOMES (ralinepag in PAH) and TETON-1 (Tyvaso in IPF), plus the $2 billion buyback announcement. Investors appear to prioritize pipeline potential—NDA/sNDA filings by summer 2026—over near-term commercial softness attributed to weather and pharmacy issues.

Forward Outlook and Key Factors to Monitor

Following Q1 results, United Therapeutics emphasized returning to sequential revenue growth across its commercial portfolio, addressing Q1 headwinds like severe weather and pharmacy disruptions that slowed patient initiations, particularly in February. Management highlighted Tyvaso DPI's resilience (9% YoY growth) and Orenitram's momentum (17th straight quarter of growth), positioning them as core drivers amid prostacyclin competition.

Pipeline catalysts loom large: Positive ADVANCE OUTCOMES data showed ralinepag reduced clinical worsening in PAH patients, with an NDA planned by end-of-summer 2026. TETON-1 demonstrated Tyvaso DPI improved lung function in IPF, supporting an sNDA filing on the same timeline. Development of ralinepag DPI for PAH, PH-ILD (pulmonary hypertension-interstitial lung disease), IPF, and progressive pulmonary fibrosis could expand addressable markets significantly if approved.

Financially, $3.47 billion in cash supports ongoing R&D ($138.2 million in Q1) and the remaining $500 million buyback capacity. Investors should watch Q2 execution for revenue rebound, regulatory progress, cost management (e.g., inventory reserves), and international expansion (ROW at 5% of sales). Broader biotech trends, including reimbursement dynamics and competitor moves, will also influence trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations